ACETQ - Aceto Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.1860
+0.0051 (+2.82%)
At close: 3:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.1809
Open0.1760
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1760 - 0.1950
52 Week Range0.0400 - 3.6300
Volume185,677
Avg. Volume594,466
Market Cap5.736M
Beta (3Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-9.7710
Earnings DateN/A
Forward Dividend & Yield0.04 (21.06%)
Ex-Dividend Date2018-09-21
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 months ago

    ACETO Completes the Sale of Its Chemicals Business Assets

    ACETO Corporation (ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management.

  • GlobeNewswire3 months ago

    ACETO Completes the Sale of Rising Pharmaceuticals

    PORT WASHINGTON, N.Y., April 22, 2019 -- ACETO Corporation (Nasdaq: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human.

  • Business Wire3 months ago

    New Mountain Capital Acquires ACETO Chemicals Business

    New Mountain Capital, LLC, a leading growth-oriented investment firm with over $20 billion in assets under management, announced today that an affiliate has agreed to acquire the chemicals business (“Aceto” or the “Company”) of ACETO Corporation (ACETQ). Headquartered in Port Washington, NY, Aceto is a leading virtual manufacturer engaged in the development, marketing, sale, and distribution of over 1,100 chemical compounds globally. Aceto has long been recognized as a leading partner to customers in the life sciences and specialty materials sectors.

  • GlobeNewswire3 months ago

    ACETO to Sell its Chemicals Business Assets to New Mountain Capital

    ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following the conclusion of a court-supervised sale process conducted under Section 363 of the U.S. Bankruptcy Code. Under that process, an asset purchase agreement between Aceto and NMC was executed, dated February 18, 2019, to sell the chemical business assets as the “stalking horse agreement”.

  • GlobeNewswire3 months ago

    ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc.

    ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court  to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business, on a cash-free and debt-free basis. The sale was conducted through a Court-supervised process under Section 363 of the Bankruptcy Code.  Under that process, Shore Suven Pharma’s purchase agreement served as the “stalking horse agreement” and an auction would have been conducted had the Company received qualified offers from other bidders reflecting potentially higher and/or otherwise better terms.